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tragedy and the discovery of teratogens, the
legalization ofabortion, andgrowing attentionto
the problems of women's alcoholism following
the women's liberation movement.
This volume amply lives up to its aim of
exploring theintertwinedrelationsbetween child
health and society from the late nineteenth
century to the present. It forms a significant
contribution to the history of medicine and
child health, opening up fascinating areas of
research thatwouldbenefitfrom similaranalysis
in other countries.
Linda Bryder,
University of Auckland
Caroline Jean Acker, Creating theAmerican
junkie: addiction research in the classic era
ofnarcotic control, Baltimore and London,
Johns Hopkins University Press, 2002, pp. x,
276, £31.00 (hardback 0-8018-6798-3).
In 1899, when Bayer Pharmaceuticals first
presented aspirin as an over-the-counter
medicine, they were hoping for a follow-up
success to the bestselling brand pharmaceutical
they had launched the previous year: Heroin.
Their advertising pitch-"Cough? The problem
has been solved by Glyco-Heroin"-had
positionedthe newdrug as aclean, scientific and
safe substitute for opium. But within a
generation, heroin would become the focus for a
vast body ofclinical research into the deviant
pathology of those who chose to take it. This
constructionofthe "junkie" asamanifestationof
a new kind of urban vice, and the medico-
scientific underpinnings of the "addict
personality", is the subject of Caroline Jean
Acker's thorough and compelling survey.
In many ways the story of heroin in the
twentieth century recapitulates that of opium
which, in the previous century, had made a
similar social transition from medicine to
menace. In 1800, opium was perhaps the single
most important drug in the Western
pharmacopoeia: cheap, widely available and
used liberally for a range of everyday disorders
ranging from gastric ailments to headaches and
nervous complaints. By 1900, it hadbeenplaced
under unprecedentedly tight medical controls
and largely substituted with more potent
synthetic preparations such as hypodermically-
injected morphine; those who persisted in using
opium without medical supervision were
reconceived as suffering from personality
disorders such as degeneration, constitutional
diathesis or moral insanity. The pathologizing
of heroin use in the early twentieth century
represents a similar process, but one buttressed
with a new medical language of psychology
and pharmacology and a new social agenda of
vice reform.
As Acker demonstrates, this new medical
language was far from unified. Its psychological
strand focused on the elucidation ofa particular
"addict personality", stressing its kinship with
otherformsofvice, suchasprostitution, andtheir
shared roots in poor impulse control and moral
weakness. By contrast, its pharmacological
strand stressed the powerful metabolic drivers of
craving, tolerance and withdrawal, carrying the
implication that addiction was a function not
so much of the addict as of the drug itself. This
latter strand manifested itself in a persistent but
largely fruitless search for a "magic bullet"
analogous to the contemporary success story of
penicillin: a "nonaddicting analgesic" which
wouldhaveheroin'stherapeutic benefits without
its drawbacks of dependence. This search,
memorably compared by Thomas Szasz to the
"search for non-flammable liquids that are easy
to ignite", persisted because, as Acker shows,
it dovetailed neatly with a broader agenda of
supply-side control by the profession at large.
What united these and other disparate
approachestotheproblemofaddictioninthefirst
half of the twentieth century was their implicit
support of the political programme of narcotic
controls and prohibitions. Acker's book ends
with the emergence of social psychologists like
AlfredLindesmith andhisUniversityofChicago
colleagues, whose work began to assemble a
critique of federal drug policy, demonstrating
that "criminaljusticesanctionsonaddictivedrug
use were cruel and ineffective". This
combined from the 1960s onwards with a
changing socialprofileofdrugusethat saw more
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addicts emerging not from the traditional milieu changes. As pharmaceutical companies gained
of the urban underclass but from the white control over research and the subsequent
suburban middle-classes, and from the 1980s marketing ofdrug therapies, the faith in science
with the disastrous spread of HIV/AIDS, gave increasingly meant a faith in pharmaceutical
impetus to new non-medical movements like companies. Healy contends that the resulting
Narcotics Anonymous and began to refocus corporatecontrol produces aculture that wasand
medical resources away from the attempt to is dominated by the dictates of apharmaceutical
eliminate drug use towards public health market rather than the needs ofpublic health.
initiatives like methadone and needle exchange. Healy combines an impressive collection of
This recent-and still only partial-shift of contemporary medical publications from the
emphasis makes Acker's book especially timely, nineteenth and twentieth centuries with avariety
revealing the pathological paradigm ofthe early ofsecondary workstoconstructacomprehensive
twentieth century to have been not so much history ofpsychopharmacology. His book
the application ofmodern science that it claimed offers a number of colourful anecdotes that
to be, as a vestigial, though powerful and breathe life into a chronologically-organized
massively-funded, extension of the generation chain of discoveries and developments.
of Victorian "moral management" which In the first halfofthebook, Healy provides an
preceded it. historical analysis of developments before the
Second World War, concentrating on
Mike Jay, professional accomplishments, controversies,
London and individual researchers that contributed to
the proliferation of psychopharmacological
David Healy, The creation of therapies in modern western medicine. In the
psychopharmacology, Cambridge, MA, and latter half ofthe book, he identifies the growing
London, Harvard University Press, 2002, influence of pharmaceutical companies in
pp. 469, £27.50 (hardback 0-674-00619-4). medical research and offers a more explicit
political critique of the corporate agenda.
Does marketing determine culture? And, what Intermittently, Healy uses comparisons with
influence does culture have on modern western Japanese case studies, as a non-western example
medicine? These questions are central to David of responses to modern psychopharmacology,
Healy's latest contribution to the history of to reinforce the substantial differences incultural
medicine in his provocative study of the rise of attitudes towards mental illness. By the book's
psychopharmacology. This book examines the conclusion, readers are left with a bleak
intersection of commercial and scientific prognosis for the disentanglement of corporate
interests in an historical investigation of interests from western medicine and, moreover,
the growing influence of pharmaceutical western culture.
companies in modern medicine, particularly in While Healy presents a compelling argument
mental health services. In this study, the history for recognizing the dangerous liaisons between
ofpsychopharmacology illuminates shifts in the corporate and public health interests, several
faith in science in nineteenth- and twentieth- other areas in his book leave the reader wanting.
century western culture. By tracing The author considers only briefly the place
psychopharmacological developments from the ofethics ineither acorporate oramedical setting,
early nineteenth century, Healy illustrates how an intriguing omission considering the subject
western societies increasingly have come to rely matter. Although Healy makes a strong argument
on modern biological medicine for revealing for the connection between corporate
the blueprints for human life, culminating in the advertising and western societies' attitudes to the
completion of the Human Genome Project. appropriate treatment of mental illness, his
Westerners became conditioned to believe in the comparison with Japan raises questions of
superiority of drug treatments over lifestyle whether the observed differences in
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